Alzheimer's disease - A sum greater than its parts?

Neurobiology of Aging

Volumn 25, Issue 6, 2004, Pages 725-733

  Adlard, Paul A ^a   Cummings, Brian J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN;

ALZHEIMER DISEASE; DISEASE COURSE; ENVIRONMENTAL FACTOR; HEREDITY; NEUROPATHOLOGY; NONHUMAN; NOTE; PRIORITY JOURNAL; RISK FACTOR; TRANSGENIC ANIMAL;

ALZHEIMER DISEASE; ANIMALS; ANIMALS, GENETICALLY MODIFIED; DISEASE MODELS, ANIMAL; ENVIRONMENT; HUMANS; NEUROFIBRILLARY TANGLES; RISK FACTORS; SENILE PLAQUES; SERUM AMYLOID A PROTEIN; TIME FACTORS;

EID: 2542625173     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2003.12.016     Document Type: Note

References (128)

1. Adlard P., Vickers J. Morphologically distinct plaque types differentially affect dendritic structure and organisation in the early and late stages of Alzheimer's disease. Acta Neuropathol (Berl). 103:2002;377-383
2. Alonso A., Zaidi T., Novak M., Barra H., Grundke-Iqbal I., Iqbal K. Interaction of tau isoforms with Alzheimer's disease abnormally hyperphosphorylated tau and in vitro phosphorylation into the disease-like protein. J Biol Chem. 276:2001;37967-37973
3. Atwood C., Martins R., Smith M., Perry G. Senile plaque composition and posttranslational modification of amyloid-beta peptide and associated proteins. Peptides. 23:2002;1343-1350
4. Augustinack J., Schneider A., Mandelkow E., Hyman B. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol (Berl). 103:2002;26-35
5. Berg L, Morris J. Diagnosis. In: Terry R, Katzman R, Bick K, editors. Alzheimer disease. New York: Raven Press; 1994. p. 9-25.
6. Blessed G., Tomlinson B., Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry. 114:1968;797-811
7. Borchelt D., Ratovitski T., van Lare J., Lee M., Gonzales V., Jenkins N., et al. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron. 19:1997;939-945
8. Brat D., Gearing M., Goldthwaite P., Wainer B., Burger P. Tau-associated neuropathology in ganglion cell tumours increases with patient age but appears unrelated to ApoE genotype. Neuropathol Appl Neurobiol. 27:2001;197-205
9. Brion J. Neurofibrillary tangles and Alzheimer's disease. Eur Neurol. 40:1998;130-140
10. Bucciantini M., Giannoni E., Chiti F., Baroni F., Formigli L., Zurdo J., et al. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature. 416:2002;507-511
11. Bussiere T., Friend P., Sadeghi N., Wicinski B., Lin G., Bouras C., et al. Stereologic assessment of the total cortical volume occupied by amyloid deposits and its relationship with cognitive status in aging and Alzheimer's disease. Neuroscience. 112:2002;75-91
12. Cai X., Golde T., Younkin S. Release of excess amyloid beta protein from a mutant amyloid beta protein precursor. Science. 259:1993;514-516
13. Cai D.M., Leem J., Greenfield J., Wang P., Kim B., Wang R., et al. Presenilin-1 regulates intracellular trafficking and cell surface delivery of beta-amyloid precursor protein. J Biol Chem. 278:2003;3446-3454
14. Caramelli P, Robitaille Y, Cholette A, Nitrini R, Gauvreau D, Joanette Y, et al. In: Iqbal K, Winblad B, Nishimura T, Takeda M, Wisniewski HW, editors. Clinicopathological study in Alzheimer's disease: senile plaques correlate with profiles of cognitive impairment. Alzheimer's disease: biology, diagnosis and therapeutics. John Wiley & Sons; 1997. p. 267-74.
15. Caramelli P., Robitaille Y., Laroche-Cholette A., Nitrini R., Gauvreau D., Joanette Y., et al. Structural correlates of cognitive deficits in a selected group of patients with Alzheimer's disease. Neuropsychiatry Neuropsychol Behav Neurol. 11:1998;184-190
16. Chartier-Harlin M., Crawford F., Houlden H., Warren A., Hughes D., Fidani L., et al. Early-onset Alzheimer's disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene. Nature. 353:1991;844-846
17. Citron M., Oltersdorf T., Haass C., McConlogue L., Hung A., Seubert R., et al. Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-protein production. Nature. 360:1992;672-674
18. Citron M., Vigo-Pelfrey C., Teplow D., Miller C., Schenk D., Johnston J., et al. Excessive production of amyloid beta-protein by peripheral cells of symptomatic and presymptomatic patients carrying the Swedish familial Alzheimer disease mutation. Proc Natl Acad Sci USA. 91:1994;11993-11997
19. Cras P., Kawai M., Lowrey D., Gozalez-deWhitt P., Greenberg B., Perry G. Senile plaques neurites in Alzheimer's disease accumulate amyloid precursor protein. Proc Natl Acad Sci USA. 88:1991;7552-7556
20. Cummings B.J. Plaques and tangles: searching for primary events in a forest of data. Neurobiol Aging. 18:1997;358-362
21. Cummings B.J., Pike C.J., Shankle R., Cotman C.W. Beta-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease. Neurobiol Aging. 17:1996;921-933
22. Cummings B.J., Satou T., Head E., Milgram N.W., Cole G.M., Savage M.J., et al. Diffuse plaques contain C-terminal Aβ42 and not Aβ40: evidence from cats and dogs. Neurobiol Aging. 17:1996;653-659
23. Cummings B.J., Su J.H., Geddes J.W., Van Nostrand W., Wagner S., Cunningham D., et al. Aggregation of the amyloid precursor protein (APP) within degenerating neurons and dystrophic neurites in Alzheimer's Disease. Neuroscience. 48:1992;763-777
24. Delacourte A. Sequential neurofibrillary degeneration in aging and Alzheimer's disease: new clues for therapy. Alzheimer's Rep. 1(Suppl 1):1998;31-32
25. Delacourte A., Sergeant N., Champain D., Wattez A., Maurage C., Lebert F., et al. Nonoverlapping but synergistic tau and APP pathologies in sporadic Alzheimer's disease. Neurology. 59:2002;398-407
26. Dickson T., King C., McCormack G., Vickers J. Neurochemical diversity of dystrophic neurites in the early and late stages of Alzheimer's disease. Exp Neurol. 1:1999;100-110
27. Duff K., Eckman C., Zehr C., Yu X., Prada C., Perez-tur J., et al. Increased amyloid-β 1-42(43) in the brains of mice expressing mutant presenilin 1. Nature. 383:1996;710-713
28. Foster N., Wilhelmsen K., Sima A., Jones M., D'Amato C., Gilman S. Frontotemporal dementia and Parkinsonism linked to chromosome 17: a consensus conference. Conference Participants. Ann Neurol. 41:1997;706-715
29. Games D., Adams D., Alessandrini R., Barbour R., Berthelette P., Blackwell C., et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature. 373:1995;523-527
30. Games D., Khan K., Soriano F., Kein P., Davis D., Bryant K., et al. Lack of Alzheimer pathology after β-amyloid protein injections in rat brain. Neurobiol Aging. 13:1992;569-576
31. Geddes J., Vowles G., Robinson S., Sutcliffe J. Neurofibrillary tangles, but not Alzheimer-type pathology. Neuropathol Appl Neurobiol. 22:1996;12-16
32. Ghiso J., Revesz T., Holton J., Rostagno A., Lashley T., Houlden H., et al. Chromosome 13 dementia syndromes as models of neurodegeneration. Amyloid. 8:2001;277-284
33. Giaccone G., Tagliavini F., Linoli G., Bouras C., Frigerio L., Frangione B., et al. Down patients: extracellular preamyloid deposits precede neuritic degeneration and senile plaques. Neurosci Lett. 97:1989;232-238
34. Goate A., Chartier-Harlin M., Mullan M., Brown J., Crawford F., Fidani L., et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature. 349:1991;704-706
35. Goedert M., Crowther R., Spillantini M. Tau mutations cause frontotemporal dementias. Neuron. 21:1998;955-958
36. Gray E. Spongiform encephalopathy: a neurocytologists viewpoint with a note on Alzheimer's disease. Neuropathol Appl Neurobiol. 12:1986;149-172
37. Gray E., Paula-Barbosa M., Roher A. Alzheimer's disease: paired helical filaments and cytomembranes. J Neuropathol Appl Neurobiol. 13:1987;91-110
38. Haass C., De Strooper B. The presenilins in Alzheimer's disease - proteolysis holds the key. Science. 286:1999;916-919
39. Hardy J. Amyloid, the presenillins and Alzheimer's disease. Trends Neurosci. 20:1997;154-159
40. Hardy J. The relationship between amyloid and tau. J Mol Neurosci. 20:2003;203-206
41. Hardy J., Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci. 12:1991;383-388
42. Hardy J., Duff K., Hardy K., Perez-Tur J., Hutton M. Genetic dissection of Alzheimer's disease and related dementias: amyloid and its relationship to tau. Nat Neurosci. 1:1998;355-358
43. Hardy J., Israël A. In search of gamma-secretase. Nature. 398:1999;466-467
44. Hardy J., Selkoe D. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 297:2002;353-356
45. Harris F., Brecht W., Xu Q., Tesseur I., Kekonius L., Wyss-Coray T., et al. Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice. Proc Natl Acad Sci USA. 100:2003;10966-10971
46. Hartley D., Walsh D., Ye C., Diehl T., Vasquez S., Vassilev P., et al. Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J Neurosci. 19:1999;8876-8884
47. Hendriks L., van Duijn C., Cras P., Cruts M., Van Hul W., van Harskamp F., et al. Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the beta-amyloid precursor protein gene. Nat Genet. 1:1992;218-221
48. Herreman A., Van Gassen G., Bentahir M., Nyabi O., Craessaerts K., Mueller U., et al. Gamma-secretase activity requires the presenilin-dependent trafficking of nicastrin through the Golgi apparatus but not its complex glycosylation. J Cell Sci. 116:2003;1127-1136
49. Hof P., Bouras C., Buee L., Delacourte A., Perl D., Morrison J. Differential distribution of neurofibrillary tangles in the cerebral cortex of dementia pugilistica and Alzheimer's disease cases. Acta Neuropathol (Berl). 85:1992;23-30
50. Hof P., Glannakopoulos P., Bouras C. The neuropathological changes associated with normal brain aging. Histol Histopathol. 11:1996;1075-1088
51. Hof P., Knabe R., Bovier P., Bouras C. Neuropathological observations in a case of autism presenting with self-injury behavior. Acta Neuropathol (Berl). 82:1991;321-326
52. Hof P, Morrison J. The cellular basis of cortical disconnection in Alzheimer disease and related dementing conditions. In: Terry R, Katzman R, Bick K, editors. Alzheimer disease. New York: Raven Press; 1994. p. 197-229.
53. Holcomb L., Gordon M., McGowan E., Yu X., Benkovic S., Jantzen P., et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med. 4:1998;97-100
54. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., et al. Correlative memory deficits Aβ elevation and amyloid plaques in transgenic mice. Science. 274:1996;99-102
55. Hutton M., Lendon C., Rizzu P., Baker M., Froelich S., Houlden H., et al. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 393:1998;702-705
56. Irizarry M., Soriano F., Mcnarmara M., Page K., Schenk D., Hyman B. Abeta deposition is associated with neuropil changes but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J Neurosci. 17:1997;7053-7059
57. Jellinger K., Bancher C. Senile dementia with tangles (tangle predominant form of senile dementia). Brain Pathol. 8:1998;367-376
58. Jorm A. Alzheimer's disease: risk and protection. Med J Aust. 167:1997;443-446
59. Kanne S., Balota D., Storandt M., McKeel D., Morris J. Relating anatomy to function in Alzheimer's disease: neuropsychological profiles predict regional neuropathology 5 years later. Neurology. 50:1998;979-985
60. Karran E., Allsop D., Christie G., Davis J., Gray C., Mansfield F., et al. Presenilins - in search of functionality. Biochem Soc Trans. 26:1998;491-496
61. Kayed R., Head E., Thompson J., Mclntire T., Milton S., Cotman C., et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 300:2003;486-489
62. Knowles R., Gomez-Isla T., Hyman B. Aβ associated neuropil changes: correlation with neuronal loss and dementia. J Neuropathol Exp Neurol. 57:1998;1122-1130
63. Knowles R., Wyart C., Buldyrev S., Cruz L., Urbane B., Hasselmo M., et al. Plaque-induced neurite abnormalities: implications for disruption of neural networks in Alzheimer's disease. Proc Natl Acad Sci USA. 96:1999;5274-5279
64. Kowall N.W., McKee A., Yankner B., Beal M. In vivo neurotoxicity of beta-amyloid [β(1-40)] and the β(25-35) fragment. Neurobiol Aging. 13:1992;537-542
65. Kril J., Patel S., Harding A., Halliday G. Neuron loss from the hippocampus of Alzheimer's disease exceeds extracellular neurofibrillary tangle formation. Acta Neuropathol (Berl). 103:2002;370-376
66. Lambert M., Barlow A., Chromy B., Edwards C., Freed R., Liosatos M., et al. Diffusible, nonfibrillar ligands derived from Abetal-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA. 95:1998;6448-6453
67. Lashuel H., Hartley D., Petre B., Walz T., Lansbury P. Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature. 418:2002;291
68. Lazarov O., Lee M., Peterson D., Sisodia S. Evidence that synaptically released beta-amyloid accumulates as extracellular deposits in the hippocampus of transgenic mice. J Neurosci. 22:2002;9785-9793
69. Lee V., Goedert M., Trojanowski J. Neurodegenerative tauopathies. Annu Rev Neurosci. 24:2001;1121-1159
70. Lewis J., Dickson D., Lin W., Chisholm L., Corral A., Jones G., et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science. 293:2001;1487-1491
71. Li Y., Xu M., Lai M., Huang Q., Castro J., DiMuzio-Mower J., et al. Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1. Nature. 405:2000;689-694
72. Mahley R. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 240:1988;622-630
73. Mann D., Esiri M. The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down's syndrome. J Neurol Sci. 89:1989;169-179
74. Mann D., Yates P., Marcyniuk B., Ravindra C. The topography of plaques and tangles in Down's syndrome patients of different ages. J Neuropathol Appl Neurobiol. 12:1986;447-457
75. Masliah E., Mallory M., Deernink T., DeTeresa R., Lamont S., Miller A., et al. Re-evaluation of the structural organization of neuritic plaques in Alzheimer's disease. J Neuropathol Exp Neurol. 52:1993;619-632
76. Masters C., Beyreuther K. Alzheimer's disease. BMJ. 316:1998;446-448
77. Mayeux R., Ottman R., Maestre G., Ngai C., Tang M., Ginsberg H., et al. Synergistic effects of traumatic head injury and apolipoprotein-ε4 in patients with Alzheimer's disease. Neurology. 45:1995;555-557
78. McKenzie J., Roberts G., Royston M. Comparative investigation of neurofibrillary damage in the temporal lobe in Alzheimer's disease Down's syndrome and dementia pugilistica. Neurodegeneration. 5:1996;259-264
79. Mesulam M. Neuroplasticity failure in Alzheimer's disease: bridging the gap between plaques and tangles. Neuron. 24:1999;521-529
80. Morris J., Price A. Pathologic correlates of nondemented aging mild cognitive impairment, and early-stage Alzheimer's disease. J Mol Neurosci. 17:2001;101-118
81. Mortimer J., van Duijn C., Chandra V., Fratiglioni L., Graves A., Heyman A., et al. Head trauma as a risk factor for Alzheimer's disease: a collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group. Int J Epidemiol. 20(Suppl 2):1991;28-35
82. Motte J., Williams R. Age-related changes in the density and morphology of plaques and neurofibrillary tangles in Down syndrome brain. Acta Neuropathol. 77:1989;535-546
83. Mullan M., Crawford F., Axelman K., Houlden H., Lilius L., Winblad B., et al. A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. Nat Genet. 1:1992;345-347
84. Murrell J., Farlow M., Ghetti B., Benson M. A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. Science. 254:1991;97-99
85. Nakagawa Y., Reed L., Nakamura M., Mclntosh T., Smith D., Saatman K., et al. Brain trauma in aged transgenic mice induces regression of established abeta deposits. Exp Neurol. 163:2000;244-252
86. Näslund J., Haroutunian V., Mohs R., Davis K., Davies P., Greengard P., et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline [see comments]. JAMA. 283:2000;1571-1577
87. Neve R., Robakis N. Alzheimer's disease: a re-examination of the amyloid hypothesis. Trends Neurosci. 21:1998;15-19
88. Nukina N., Kanazawa I., Mannen T., Uchida Y. Accumulation of amyloid precursor protein and beta-protein immunoreactivities in axons injured by cerebral infarct. Gerontology. 38(Suppl 1):1992;10-14
89. Oddo S., Caccamo A., Shepherd J., Murphy M., Golde T., Kayed R., et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 39:2003;409-421
90. Paula-Barbosa M., Tavares M., Cadete-Leite A. A quantitative study of frontal cortex dendritic microtubules in patients with Alzheimer's disease. Brain Res. 416:1987;139-142
91. Pigino G., Morfini G., Pelsman A., Mattson M., Brady S., Busciglio J. Alzheimer's presenilin 1 mutations impair kinesin-based axonal transport. J Neurosci. 23:2003;4499-4508
92. Pike C., Walencewicz A., Glabe C., Cotman C.W. In vitro aging of beta-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res. 563:1991;311-314
93. Poorkaj P., Bird T., Wijsman E., Nemens E., Garruto R., Anderson L., et al. Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann Neurol. 43:1998;815-825
94. Poulos B., Crystal H., Katz M., Kuslansky G., Grober E., Lipton R., et al. Amyloid burden determined by image analysis correlates with conventional histochemical method and clinical measures of cognitive decline. J Neuropathol Exp Neurol. 56:1997;615
95. Praprotnik D., Smith M., Richey P., Vinters H., Perry G. Filament heterogeneity within the dystrophic neurites of senile plaques suggests blockage of fast axonal transport in Alzheimer's disease. Acta Neuropathol. 91:1996;226-235
96. Rapoport M., Dawson H., Binder L., Vitek M., Ferreira A. Tau is essential to beta-amyloid-induced neurotoxicity. Proc Natl Acad Sci USA. 99:2002;6364-6369
97. Rasmusson D., Brandt J., Martin D., Folstein M. Head injury as a risk factor in Alzheimer's disease. Brain Inj. 3:1995;213-219
98. Roberts G., Allsop D., Bruton C. The occult aftermath of boxing. J Neurol Neurosurg Psychiatry. 53:1990;373-378
99. Roberts G., Gentleman S., Lynch A., Murray L., Landon M., Graham D. Beta amyloid protein deposition in the brain after severe head injury: implications for the pathogenesis of Alzheimer's disease. J Neurol Neurosurg Psychiatry. 57:1994;419-425
100. Sampson V., Morrison J., Vickers J. The cellular basis for the relative resistance of parvalbumin and calretinin immunoreactive neocortical neurons to the pathology of Alzheimer's disease. Exp Neurol. 145:1997;295-302
101. Schwab C., Steele J., Akiyama H., McGeer E., McGeer P. Relationship of amyloid beta/A4 protein to the neurofibrillary tangles in Guamanian Parkinsonism-dementia. Acta Neuropathol (Berl). 90:1995;287-298
102. Sheng J., Price D., Koliatsos V. Disruption of corticocortical connections ameliorates amyloid burden in terminal fields in a transgenic model of Abeta amyloidosis. J Neurosci. 22:2002;9794-9799
103. Simchowicz T. Histologische Studien iiber die senile demenz. Histol Histopathol Arb. 4:1910;267
104. Smith D., Chen X., Nonaka M., Trojanowski J., Lee V., Saatman K., et al. Accumulation of amyloid beta and tau and the formation of neurofilament inclusions following diffuse brain injury in the pig. J Neuropathol Exp Neurol. 58:1999;982-992
105. Spillantini M., Murrell J., Goedert M., Farlow M., Klug A., Ghetti B. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci USA. 13:1998;7737-7741
106. Stamer K., Vogel R., Thies E., Mandelkow E., Mandelkow E. Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress. J Cell Biol. 156:2002;1051-1063
107. Steiner H., Capell A., Leimer U., Haass C. Genes and mechanisms involved in beta-amyloid generation and Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci. 249:1999;266-270
108. Stephenson D., Clemens J. In vivo effects of beta-amyloid implants in rodents: lack of potentiation of damage associated with transient global forebrain ischemia. Brain Res. 586:1992;235-246
109. 717) mutants. Science. 264:1994;1336-1340
110. Takadera T., Sakura N., Mohri T., Hashimoto T. Toxic effect of a beta-amyloid peptide (beta-22-35) on the hippocampal neuron and its prevention. Neurosci Lett. 161:1993;41-44
111. Tamaoka A., Odaka A., Ishibashi Y., Usami M., Sahara N., Suzuki N., et al. APP717 missense mutation affects the ratio of amyloid beta protein species (a beta 1-42/43 and a beta 1-40) in familial Alzheimer's disease brain. J Biol Chem. 269:1994;32721-32724
112. Terry R. Neuropathological changes in Alzheimer disease. Prog Brain Res. 101:1994;383-390
113. Terry R. The pathogenesis of Alzheimer disease: an alternative to the amyloid hypothesis. J Neuropathol Exp Neurol. 55:1996;1023-1025
114. Tokuda T., Ikeda S., Yanagisawa N., Ihara Y., Glenner G. Re-examination of ex-boxers' brains using immunohistochemistry with antibodies to amyloid beta-protein and tau protein. Acta Neuropathol (Berl). 82:1991;280-285
115. Trojanowski J., Ishihara T., Higuchi M., Yoshiyama Y., Hong M., Zhang B., et al. Amyotrophic lateral sclerosis/Parkinsonism dementia complex: transgenic mice provide insights into mechanisms underlying a common tauopathy in an ethnic minority on Guam. Exp Neurol. 176:2002;1-11
116. Uryu K., Laurer H., Mclntosh T., Pratico D., Martinez D., Leight S., et al. Repetitive mild brain trauma accelerates Abeta deposition, lipid peroxidation, and cognitive impairment in a transgenic mouse model of Alzheimer amyloidosis. J Neurosci. 22:2002;446-454
117. Van Broeckhoven C. Genetics of Alzheimer's disease: what have we learned ? Alzheimer's Rep. 1(Suppl):1998;21-22
118. Van Groen T., Liu L., Ikonen S., Kadish I. Diffuse amyloid deposition but not plaque number, is reduced in amyloid precursor protein/presenilin 1 double-transgenic mice by pathway lesions. Neuroscience. 119:2003;1185-1197
119. Verdile G., Martins R., Duthie M., Holmes E., St George-Hyslop P., Fraser P. Inhibiting amyloid precursor protein C-terminal cleavage promotes an interaction with presenilin 1. J Biol Chem. 275:2000;20794-20798
120. Vermersch P., David J., Frigard B., Fallet-Bianco C., Wattez A., Petit H., et al. Cortical mapping of Alzheimer pathology in brains of aged non-demented subjects. Prog Neuropsychopharmacol Biol Psychiatry. 19:1995;1035-1047
121. Vickers J., Chin D., Edwards A., Sampson V., Harper C., Morrison J. Dystrophic neurite formation associates with age-related β amyloid deposition in the neocortex: clues to the genesis of neurofibrillary pathology. Exp Neurol. 141:1996;1-11
122. Vickers J., Dickson T., Adlard P., Saunders H., King C., McCormack G. The cause of neuronal degeneration in Alzheimer's disease. Prog Neurobiol. 60:2000;139-165
123. Vidal R., Frangione B., Rostagno A., Mead S., Revesz T., Plant G., et al. A stop-codon mutation in the BRI gene associated with familial British dementia. Nature. 399:1999;776-781
124. Weldon D., Rogers S., Ghilardi J., Finke M., Cleary J., O'Hare E., et al. Fibrillar beta-amyloid induces microglial phagocytosis expression of inducible nitric oxide synthase and loss of a select population of neurons in the rat CNS in vivo. J Neurosci. 18:1998;2161-2173
125. Wisniewski K., Wisniewski H., Wen G. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann Neurol. 17:1985;272-282
126. Wolfe M., Xia W., Ostaszewski B., Diehl T., Kimberly W., Selkoe D. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature. 398:1999;513-517
127. Yankner B. Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron. 16:1996;921-932
128. Zerovnik E. Amyloid-fibril formation. Proposed mechanisms and relevance to conformational disease. Eur J Biochem. 269:2002;3362-3371